Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Inclusion Criteria: * A confirmed severe form of any type of pyoderma with lesions of the skin and muscle tissue was diagnosed * Male or female, age ≥ 21 years * Previous treatment with TNF antagonists (infliximab, adalimumab, etanercept, certolizumab, golimumab) ended no earlier than 30 days before starting therapy * Secondary treatment failure with up to one previous TNFα antagonist treatment (from the list above) * Secondary failure of corticosteroid treatment * Adequate hematologic, hepatic, and renal function * Written informed consent. Exclusion Criteria: * History of primary resistance or intolerance to any TNFα antagonist. * History of congestive heart failure or current, controlled or uncontrolled * Women who are pregnant or breastfeeding, or women of childbearing age if no effective method of contraception has been used during and for 3 months after the trial * Men, if no effective contraceptive method was used during the study and for 3 months afterward * Any prior exposure to Hu5F9-G4 or other CD47 targeting agents * Previous allogeneic stem cell transplant within 6 months prior to enrollment, active graft versus host disease (GVHD), or need for graft-associated immunosuppression * Refusal to sign the informed consent